Gruis NA - Search Results

1

Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression.

Gruis NA, Weaver-Feldhaus J, Liu Q, Frye C, Eeles R, Orlow I, Lacombe L, Ponce-Castaneda V, Lianes P, Latres E, et al. Gruis NA, et al. Am J Pathol. 1995 May;146(5):1199-206. Am J Pathol. 1995. PMID: 7747814 Free PMC article.

2

Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds.

Gruis NA, van der Velden PA, Sandkuijl LA, Prins DE, Weaver-Feldhaus J, Kamb A, Bergman W, Frants RR. Gruis NA, et al. Nat Genet. 1995 Jul;10(3):351-3. doi: 10.1038/ng0795-351. Nat Genet. 1995. PMID: 7670475

3

CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines.

Liu Q, Neuhausen S, McClure M, Frye C, Weaver-Feldhaus J, Gruis NA, Eddington K, Allalunis-Turner MJ, Skolnick MH, Fujimura FK, et al. Liu Q, et al. Among authors: gruis na. Oncogene. 1995 Mar 16;10(6):1061-7. Oncogene. 1995. PMID: 7700630

4

Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus.

Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver-Feldhaus J, et al. Kamb A, et al. Among authors: gruis na. Nat Genet. 1994 Sep;8(1):23-6. doi: 10.1038/ng0994-22. Nat Genet. 1994. PMID: 7987388

5

Localization of a putative tumor suppressor gene by using homozygous deletions in melanomas.

Weaver-Feldhaus J, Gruis NA, Neuhausen S, Le Paslier D, Stockert E, Skolnick MH, Kamb A. Weaver-Feldhaus J, et al. Among authors: gruis na. Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7563-7. doi: 10.1073/pnas.91.16.7563. Proc Natl Acad Sci U S A. 1994. PMID: 8052620 Free PMC article.

6

A cell cycle regulator potentially involved in genesis of many tumor types.

Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS 3rd, Johnson BE, Skolnick MH. Kamb A, et al. Among authors: gruis na. Science. 1994 Apr 15;264(5157):436-40. doi: 10.1126/science.8153634. Science. 1994. PMID: 8153634

7

CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines.

Liu Q, Neuhausen S, McClure M, Frye C, Weaver-Feldhaus J, Gruis NA, Eddington K, Allalunis-Turner MJ, Skolnick MH, Fujimura FK, et al. Liu Q, et al. Among authors: gruis na. Oncogene. 1995 Dec 7;11(11):2455. Oncogene. 1995. PMID: 8570198 No abstract available.

8

Infrequent CDKN2 (MTS1/p16) gene alterations in human primary breast cancer.

Berns EM, Klijn JG, Smid M, van Staveren IL, Gruis NA, Foekens JA. Berns EM, et al. Among authors: gruis na. Br J Cancer. 1995 Oct;72(4):964-7. doi: 10.1038/bjc.1995.442. Br J Cancer. 1995. PMID: 7547249 Free PMC article.

9

CDKN2 explains part of the clinical phenotype in Dutch familial atypical multiple-mole melanoma (FAMMM) syndrome families.

Gruis NA, Sandkuijl LA, van der Velden PA, Bergman W, Frants RR. Gruis NA, et al. Melanoma Res. 1995 Jun;5(3):169-77. doi: 10.1097/00008390-199506000-00005. Melanoma Res. 1995. PMID: 7640518

10

A locus linked to p16 modifies melanoma risk in Dutch familial atypical multiple mole melanoma (FAMMM) syndrome families.

van der Velden PA, Sandkuijl LA, Bergman W, Hille ET, Frants RR, Gruis NA. van der Velden PA, et al. Among authors: gruis na. Genome Res. 1999 Jun;9(6):575-80. Genome Res. 1999. PMID: 10400925 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

160 results

Search Page

Filters